Human psychopharmacology of Ecstasy (MDMA): A review of 15 years of empirical research

Human Psychopharmacology

Volumn 16, Issue 8, 2001, Pages 557-577

  Parrott, A C ^a  

^a UNIVERSITY OF EAST LONDON   (United Kingdom)

Author keywords

Cognition; Ecstasy; MDMA; Memory; Neurotoxicity; Serotonin

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 5 HYDROXYINDOLEACETIC ACID; ALCOHOL; AMPHETAMINE; BARBITURIC ACID DERIVATIVE; CANNABIS; CENTRAL STIMULANT AGENT; COCAINE; ILLICIT DRUG; LYSERGIDE; NEUROTRANSMITTER; NICOTINE; OPIATE; PLACEBO; PSILOCYBINE; SEROTONIN;

AMNESIA; APPETITE DISORDER; AROUSAL; CLINICAL RESEARCH; COGNITIVE DEFECT; CONTROLLED STUDY; CROWDING; DANCING; DEPRESSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABUSE PATTERN; DRUG EFFECT; ENVIRONMENTAL TEMPERATURE; FEMALE; HIPPOCAMPUS; HUMAN; HYPERACTIVITY; HYPERTHERMIA; INHIBITION KINETICS; LEARNING DISORDER; LETHARGY; MALE; MONOAMINERGIC SYSTEM; NEUROTOXICITY; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; PSYCHOPHARMACOLOGY; PSYCHOPHYSIOLOGY; RAT; REBOUND; REVIEW; SEROTONIN RELEASE; SEROTONIN SYNDROME; SEROTONIN UPTAKE; SEROTONINERGIC SYSTEM; SEXUAL DEVIATION; SLEEP DISORDER; TOXICOKINETICS; VOLUNTEER; WELLBEING;

EID: 0035669358     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.351     Document Type: Review

References (130)

1. Sleep in abstinent users of MDMA
2. Chemical analysis of Ecstasy pills
3. MDMA-induced neurotoxicity: Parameters of degeneration and recovery of brain serotonin neurones
4. Ibiza uncovered: Changes in substance use and sexual behavior amongst young people visiting an international night-life resort
5. The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, para-chloroamphetamine and fenfluramine induce 5-hydroxytrypamine release via a common mechanism blocked by fluoxetine and cocaine
6. Memory impairment in abstinent MDMA ('ecstasy') users
7. MDMA (ecstasy) neurotoxicity: Assessing and communicating the risks
8. 3,4-Methylenedioxymethamphetamine (ecstasy)-induced learning and memory impairments depend on the age of exposure during early development
9. MDMA and human sexual function
10. Ecstasy abuse and dependence: Applicability and reliability of DSM-IV criteria among adolescents and young adults
11. Ecstasy psychosis and flashbacks
12. The relative contributions of ecstasy and cannabis to cognitive impairment
13. Is MDMA (ecstasy) neurotoxic in humans? An overview of evidence and methodological problems in research
14. Mood and cognitive effects of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'): Week-end 'high' followed by mid-week 'low'
15. Effects of ambient temperature on hyperthermia and hyperkinesis induced by 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy') in rats
16. Level of use of 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) in humans correlates with EEG power and coherence
17. Ecstasy in recreational users: Self-reported psychological and physiological effects
18. Non-linear pharmacokinetics of MDMA ('ecstasy') in humans
19. Reorganization of ascending serotonin axon projections in animals previously exposed to the recreational drug 3,4-methylenedioxymethamphetamine
20. Neuropsychological cognitive profiles of heavy MDMA (ecstasy) users
21. Ecstasy/MDMA related cognitive deficits: A function of dosage rather than awareness of problems
22. Auditory verbal learning in drug free ecstasy polydrug users
23. 3,4-methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by [H(2)(15)0]-PET in healthy humans
24. Serotonergic function after 3,4-Methylenedioxymethamphetamine
25. Ecstasy, serotonin syndrome and the treatment of hyperpyrexia
26. Serotonin syndrome: History and risk
27. The serotonin syndrome and its treatment
28. Effects of 3,4-Methylenedioxymethamphetamine on thermoregulatory responses in the rat
29. Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers
30. Impaired cognitive performance in drug free users of recreational ecstasy. MDMA
31. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or ecstasy)
32. Subjective reports of the effects of MDMA in a clinical setting
33. A method for conducting therapeutic sessions with MDMA
34. The use of amphetamines, ecstasy, and LSD in the European community: A review of data on consumption patterns
35. Deconstructing ecstasy: The politics of MDMA research
36. Subjective ratings of prospective memory deficits in MDMA ('ecstasy') users
37. 3,4-Methylenedioxy analogues of amphetamine: Defining the risks to humans
38. Toxicity and deaths from 3,4-methylenedioxymethamphetamine ('ecstasy')
39. Psychological effects of MDE in normal subjects
40. Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and its congeners
41. Ecstasy (MDMA) dependence
42. Was it MDMA?
43. Striatal serotonin is depleted in brain of human MDMA (ecstasy) user
44. Chronic 3,4-methylenedioxymethamphetamine (MDMA) use: Effects on mood and neuropsychological function?
45. Caveat emptor: Researchers beware
46. Gender differences in the subjective effects of MDMA
47. Which neuroreceptors mediate the subjective effects of MDMA in humans?
48. The 'E' Plan Diet
49. Former chronic methylenedioxymethamphetamine (MDMA or ecstasy) users report mild depressive symptoms
50. Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat
51. Cognitive performance in (+ / -) 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') users: A controlled study
52. (+ / -) 3,4-Methylenedioxymethamphetamine ('ecstasy')-induced serotonin neurotoxicity: Clinical studies
53. Lasting neuropsychiatric sequelae of (+ / -) methylenedioxymethamphetamine ('ecstasy') in recreational users
54. Reinforcing subjective experience of (+ / -) 3,4-methylenedioxymethamphetamine ('ecstasy') may be separable from its neurotoxic actions: Clinical evidence
55. Caveat emptor: Editors beware
56. 3,4-Methylenedioxymethamphetamine (MDMA)-induced brain serotonin neurotoxicity: Clinical studies
57. Serotonin neurotoxicity after (+ / -) 3,4-methylenedioxymethamphetamine (MDMA: 'ecstasy'): A controlled study in humans
58. Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy')
59. Positron emission tomographic evidence of toxic effect of MDMA ('ecstasy') on brain serotonin neurones in human beings
60. MDMA: Its history and pharmacology
61. Congenital anomolies after perinatal ecstasy exposure
62. Long term psychiatric and cognitive effects of MDMA use
63. Drug use amongst undergraduates: Current use and 10 year trends
64. Ecstasy and neurodegeneration
65. Recreational drug use and psychobiological problems, collaborative UK/Italy study (5): Ecstasy (MDMA) polydrug findings
66. Psychobiological problems in recreational ecstasy polydrug users: A prospective study
67. The new psychedelic culture: LSD, ecstasy, rave parties, and the Grateful Dead
68. Recreational use of 'ecstasy' (MDMA) is associated with elevated impulsivity
69. Memory deficits associated with recreational use of 'ecstasy' (MDMA)
70. Ecstasy (MDMA): A review of its possible persistent psychological effects
71. A review of the role of serotonin receptors in psychiatric disorders
72. MDMA, mood and memory: The agnosia of the ecstasy
73. Does cigarette smoking cause stress?
74. Human research on MDMA (3,4-methylene-dioxymethamphetamine) neurotoxicity: Cognitive and behavioral indices of change
75. Cigarette smoking does cause stress
76. Nicotine/cigarette dependency: A cause of depression?
77. Recreational ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity
78. Ecstasy (MDMA) effects upon mood and cognition; before, during, and after a Saturday night dance
79. Wobble, rave, inhale or crave: Psychoactive drugs of abuse symposium
80. Cognitive performance in recreational users of MDMA or 'ecstasy': Evidence for memory deficits
81. Psychobiological problems in heavy 'ecstasy' (MDMA) polydrug users
82. Ecstasy polydrug users and other recreational drug users in Britain and Italy: Psychiatric symptoms and psychobiological problems
83. Ecstasy and new patterns of drug use: A normal population study Addiction
84. Memory decrements but trends towards faster mental rotation, in abstinent ecstasy/MDMA users
85. Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users
86. Neuroendocrine and mood responses to intravenous tryptophan in of 3,4-methylenedioxymethamphetamine (MDMA) users
87. Memory disturbances in 'ecstasy' users are correlated with an altered brain serotonin neurotransmission
88. Investigating the potential neurotoxicity of ecstasy (MDMA): An imaging approach
89. Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals
90. Aminergic metabolites in cerebrospinal fluid of humans previously exposed to MDMA: Preliminary observations
91. (+ / -) 3,4-Methylenedioxymethamphetamine (MDMA, 'ecstasy')-induced serotonin neurotoxicity: Studies in animals
92. Differential effects of ecstasy and cannabis on self reports of memory ability: A web-based study
93. Cognitive performance amongst recreational users of 'Ecstasy'
94. Chronic atypical psychosis associated with MDMA ('Ecstasy') abuse
95. Potential human neurotoxicity of MDMA ('ecstasy'): Subjective self-reports, evidence from an Italian drug addiction centre and clinical case studies
96. MDMA ('ecstasy') abuse: Psychopathological features and craving for chocolate: A case series
97. MDMA ('ecstasy') consumption in the context of polydrug abuse: A report on 150 patients
98. Neurotoxicity of the psychedelic amphetamine methylenedioxymethamphetamine
99. Methylenedioxymethamphetamine: A potentially neurotoxic amphetamine analogue
100. Tryptophan depletion impairs memory consolidation but improves focused attention in healthy young volunteers
101. Is the use of ecstasy and hallucinogens increasing?
102. Reduced in vivo binding to serotonin transporters in the cerebral cortex of MDMA ('ecstasy') users
103. The background and chemistry of MDMA
104. Characteristics of three new psychotomimetics
105. Psychiatric disorders in recreational ecstasy (MDMA) users: A literature review focusing upon personal predisposition factors and drug histories
106. Recreational MDMA use in Sydney: A profile of ecstasy users and their experiences with the drug
107. A pure amnesic syndrome after MDMA ('ecstasy') ingestion
108. An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine
109. Ecstasy use and policy response in the Netherlands
110. Monitoring synthetic drug markets, trends and public health
111. Emergency medical assistance during a mass gathering
112. Ecstasy use in Australia: Patterns of use and associated harm
113. The demethylenation of 3,4-methylenedioxyamphetamine ('ecstasy') by debrisoquinine hydroxylase (CYP2D6)
114. Spatial and object recognition performance of regular MDMA users assessed in virtual reality
115. Reduced calorie intake in the week following weekend MDMA (ecstasy) use
116. Cognitive task performance profiles of current and former 'ecstasy' (MDMA) users
117. Cognitive performance and serotonergic function in users of ecstasy
118. Psychological and cardiovascular effects and short-term sequelae of MDMA ('ecstasy') in MDMA-naive healthy humans
119. Is a single dose of MDMA harmless?
120. Caveat emptor: Editors beware
121. Working memory deficits in current and previous users of MDMA ('ecstasy')
122. Alcohol and drug use in UK university students
123. Ecstasy and the Dutch rave scene: A socio-epidemiological study
124. Amphetamine like stimulants
125. Memory impairment in abstinent MDMA ('ecstasy') users: A longitudinal investigation